News & Moves: CDXS, CVV, IOSP, XNPT

(RTTNews) - Codexis Earnings Report Decoded…

Codexis Inc. (CDXS), a developer of biocatalysts, has reported a significant year-over-year growth in revenue categories and a substantial decline in operating expenses this quarter.

Revenues for the quarter ended September 30, 2014 were $7.5 million, a 90% increase from $3.9 million in the third quarter of 2013.

For full year 2014, the company continues to expect revenues of between $35 million and $38 million, representing growth of 10% to 19% compared to the prior year.

In July of this year, Codexis granted GlaxoSmithKline a license to use Codexis' proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The agreement marks the first time that Codexis has licensed its protein engineering platform technology to any party in the healthcare field.

CDXS closed Tuesday's trading at $2.58, down 0.39%.

What Awaits CVV…

CVD Equipment Corp. (CVV), which has been experiencing a continuing trend of high orders levels, has received in excess of $5.6 million in new orders during the month October 2014. The company remains confident that its new order bookings momentum will continue into the future.

The company reported revenue of $4.4 million in Q1, 2014 and $6.11 million in Q2, 2014. The company is scheduled to report third quarter financial results on Nov.18, 2014.

CVV has lost more than 27% of its value year-to-date. The stock closed Tuesday's trading at $10.55, up 1.64%.

IOSP Paints A Bright Quarter...

Innospec Inc. (IOSP), a specialty chemical company, has had sequential and year-over-year increase in the quarterly results reported so far this year despite the challenging geopolitical issues and heightened competitive pressures, particularly in the EMEA (Europe, Middle East & Africa) region.

In the third quarter ended September 30, 2014, total net sales are $228.2 million, up from $221.3 million in Q2, 2014 and an 18 percent increase from $192.8 million in Q3, 2013.

Net income is $20.8 million or $0.83 per share in Q3, 2014 compared to $18.5 million or $0.75 per share in Q2, 2014 and $14.0 million or $0.58 per share in Q3, 2013.

The company has also declared a biannual dividend of $0.28 per common share for the second half of 2014, which will be paid on November 26, 2014 to shareholders of record on November 17, 2014. This brings the annual dividend to 55 cents per share, which represents a 10 percent increase over the 2013 payments.

IOSP has lost more than 14% of its value year-to-date. The stock closed Tuesday's trading at $39.66, down 1.17%.

XNPT To Keep On Your Radar...

Biopharmaceutical company XenoPort Inc. (XNPT) is a stock to keep on your radar, given the improving financial metrics.

In the third quarter ended September 30, 2014, the net income is $8.3 million or $0.13 per share on total revenues of $31.1 million. The Q3, 2014 revenue included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Reckitt Benckiser Pharmaceuticals and $5.6 million in HORIZANT net product sales.

The company posted a net loss of $18.82 million or $0.39 per share and total revenue of $2.53 million in Q3, 2013. The Q3, 2013 revenue included $2.0 million in HORIZANT net product sales.

The company signed an agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) in September of this year to conduct a clinical trial of HORIZANT Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). While XenoPort will supply clinical trial material, the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT.

A phase II trial of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis is underway. The top-line data from this trial are expected in the third quarter of 2015.

XNPT closed Tuesday's trading at $6.54, down 2.10%.